Skip to main content

Cheplapharm has major plans for the Basel Area

| News

Cheplapharm has major plans for the Basel Area


Cheplapharm Switzerland will seek to drive the growth of the group, and execute global acquisitions of established medicines from large pharmaceutical companies for the entire Cheplapharm Group. Agnes Wasem, formerly of Roche, has been appointed as Managing Director.

Agnes Wasem is the Managing Director of Cheplapharm Switzerland (image: Cheplapharm)

Cheplapharm Switzerland based in Binningen, the Swiss subsidiary of Cheplapharm Arzneimittel GmbH based in Greifswald in Germany, will now seek to drive the growth of the group, and execute global acquisitions of established medicines from large pharmaceutical companies for the entire Cheplapharm Group. Swissmedic, the Swiss Agency for Therapeutic Products, has already granted the neccessary operating license.

Cheplapharm is a family-owned company that has been acquiring well-known and well-established medicines from the research-based pharmaceutical industry for over 20 years and transferring them to an existing global network of partners for production and distribution. The group is represented in over 145 countries worldwide with more than 3,200 marketing authorizations.

New location has great strategic importance

As the CEO of the group, Edeltraud Lafer, emphasized in a press release, the proximity to the Big Pharma groups was of “great strategic importance” when choosing the new location. The authorities in the canton of Basel-Landschaft recently assured the company of their support. The meeting at Cheplapharm’s premises in Binningen was attended by representatives from Economic Development Baselland and the investment and innovation promotion agency Basel Area Business & Innovation.

Agnes Wasem is the Managing Director of Cheplapharm Switzerland LLC, which was founded in 2023. The 40-year-old qualified business lawyer holds a Postgraduate Diploma in European Competition Law from King’s College London. Prior to joining Cheplapharm, Wasem spent a decade working in various executive positions at F. Hoffmann-La Roche in Basel. “I already know Cheplapharm from many joint divestment projects at Roche, in which Roche products were transferred into the trusting hands of Cheplapharm”, she explains in the press release. Wasem goes on to express her delight at having the opportunity to now “build up the Swiss affiliate”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.